Partnership to leverage the Helix Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
The strategic acquirer maintains a nationwide presence in the LTC pharmacy space
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
To create leading company developing medicines targeting metalloenzymes
The proposed initiative is conceptualised with an objective to identify, support, and promote innovative research ideas in healthcare research
The term of O&M is for 15 years with a lock in period of 5 years for the Company and 15 years for VHPL & Bharathi Education trust.
Subscribe To Our Newsletter & Stay Updated
